Advertisement
Advertisement
ANAB
AnaptysBio, Inc. Common Stock
46.45
USDSponsored
+0.87
+1.91%
Nov 06, 15:59 UTC -5
Closed
After-Market
46.45
0.00
0.00%
AnaptysBio, Inc. Common Stock (ANAB) Earnings
ANAB Earnings Reports
Positive Surprise Ratio
ANAB beat 24 of 39 last estimates.
62%
Next Report
Next Week
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
$39.16M
/$0.60
Implied change from Q2 26 (Revenue/ EPS)
+42.47%
/+757.14%
Implied change from Q3 25 (Revenue/ EPS)
-48.69%
/+15.38%
AnaptysBio, Inc. Common Stock earnings per share and revenue
On Sep 21, 2026, ANAB reported earnings of 0.07 USD per share (EPS) for Q2 26, beating the estimate of 0.00 USD, resulting in a 2158.06% surprise. Revenue reached 27.49 million, compared to an expected 31.73 million, with a -13.36% difference. The market reacted with a +4.33% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of 0.60 USD, with revenue projected to reach 39.16 million USD, implying an increase of 757.14% EPS, and increase of 42.47% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were AnaptysBio, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, AnaptysBio, Inc. Common Stock reported EPS of $0.07, beating estimates by 2158.06%, and revenue of $27.49M, -13.36% below expectations.
How did the market react to AnaptysBio, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 4.33%, changed from $55.47 before the earnings release to $57.87 the day after.
When is AnaptysBio, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for AnaptysBio, Inc. Common Stock's next earnings report?
Based on 10
analysts, AnaptysBio, Inc. Common Stock is expected to report EPS of $0.60 and revenue of $39.16M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.